BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36369496)

  • 1. Obinutuzumab and reduced bendamustine is effective for elderly patients with follicular lymphoma.
    Masamoto Y; Shimura A; Honda A; Taoka K; Maki H; Kurokawa M
    Ann Hematol; 2023 Jan; 102(1):243-244. PubMed ID: 36369496
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
    Haukaas FS; Ohna A; Krivasi T
    Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
    Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
    J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
    Ueda Y; Asakura S; Wada S; Saito T; Yano T
    Intern Med; 2022 Aug; 61(16):2523-2526. PubMed ID: 35650124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
    Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
    Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
    Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
    Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
    D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
    Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
    [No Abstract]   [Full Text] [Related]  

  • 9. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Rafia R; Pandor A; Davis S; Stevens JW; Harnan S; Clowes M; Sorour Y; Cutting R
    Pharmacoeconomics; 2018 Oct; 36(10):1143-1151. PubMed ID: 29594951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
    Trotman J; Cheah CY; Marlton P; Opat S
    Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
    Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
    Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study.
    Yamasaki S; Matsushima T; Minami M; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2022 Jan; 101(1):209-211. PubMed ID: 33392703
    [No Abstract]   [Full Text] [Related]  

  • 14. High-risk follicular lymphoma: Treatment options.
    Kahl B
    Hematol Oncol; 2021 Jun; 39 Suppl 1():94-99. PubMed ID: 34105813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma.
    Ma J; Zhao D; Zhen B; Xia Y; Gong Q; Chen W
    J Comp Eff Res; 2023 Dec; 12(12):e230073. PubMed ID: 37916709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
    Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
    Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
    Guzauskas GF; Masaquel A; Thuresson PO; Dawson K; Veenstra DL
    Leuk Lymphoma; 2019 Jul; 60(7):1668-1676. PubMed ID: 30632837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.
    Yamashita-Kashima Y; Yorozu K; Fujimura T; Kawasaki N; Kurasawa M; Yoshiura S; Harada N; Kondoh O; Yoshimura Y
    Int J Hematol; 2022 Jun; 115(6):860-872. PubMed ID: 35301681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.